Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Cancer drugs funding

Wales will not have a Cancer Drugs Fund, health minister says

A Cancer Drugs Fund has been ruled out for Wales, despite a petition with 98,000 signatures.

Mark Drakeford (pictured), health minister for Wales, says there will not be a Cancer Drugs Fund for Wales

Source: Matthew Horwood / Alamy

Mark Drakeford, health minister for Wales, has “no intention” of introducing a cancer drugs fund in Wales, claiming it is not ethical and is unpopular with the public

Wales will not have a Cancer Drugs Fund, despite a 98,000-signature petition calling for equity of access to cancer drugs for patients in England and Wales being handed to the Welsh Assembly on 5 November 2014.

Mark Drakeford, health minister for Wales, ruled out the fund during health minister’s questions at the meeting.

He told the meeting that the Welsh Government has “no intention” of introducing a scheme that he claimed was not ethical, lacked clinical support, was unpopular with the public and would deliver a “lesser service” for cancer patients in Wales.

Darren Millar, Conservative assembly member for Clwyd West, called the government’s stance an “obvious injustice” and said that patients in England were securing better clinical outcomes as a direct result of their access to a Cancer Drugs Fund.

But the minister rejected Millar’s accusation. “We have a system that is fair to all patients, that is clinically driven and that provides good outcomes at a cost effective price. That is the right way to do things,” he said. More than half of applications to Wales’s Individual Patient Funding Request (IPFR) process, which allows consideration of medicines not routinely available through the Welsh NHS, result in a drug being made available, he told the Assembly.

England’s fund, recently increased to a value of £280m a year until 2016, provides access to cancer drugs that have not been approved by the National Institute for Health and Care Excellence and are not available through NHS England. Drakeford also announced that, as a result of a review, the IPFR process is being strengthened to include access to orphan drugs for patients with rare diseases and the work of each regional IPFR panel is to be centrally coordinated to ensure consistency.

Like Wales, Scotland and Northern Ireland have no Cancer Drugs Fund: their devolved governments have their own systems for decision-making on patient access to non-approved drugs. However, arrangements in Northern Ireland are under review. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067145

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmaceutical Statistics

    Pharmaceutical Statistics

    This book on basic statistics has been specifically written for pharmacy students.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Mark Drakeford (pictured), health minister for Wales, says there will not be a Cancer Drugs Fund for Wales

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.